Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: Discovery, optimization, and biological evaluation

Journal of Medicinal Chemistry

Volumn 56, Issue 5, 2013, Pages 2045-2058

  Yang, Peng ^a,b   Wang, Liping ^a,b   Feng, Rentian ^a,b   Almehizia, Abdulrahman A ^a,b   Tong, Qin ^a,b   Myint, Kyaw Zeyar ^a,b   Ouyang, Qin ^a,b   Alqarni, Mohammed Hamed ^a,b   Wang, Lirong ^a,b   Xie, Xiang Qun ^a,b,c  

^a Universigy of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; N ((3S,5S,7S) ADAMANTAN 1 YL) N (4 (DIETHYLAMINO)BENZYL) 3 METHYLBENZENESULFONAMIDE; N ((3S,5S,7S) ADAMANTAN 1 YL) N (4 (DIETHYLAMINO)BENZYL) 4 FLUOROBENZENESULFONAMIDE; N (4 (DIETHYLAMINO)BENZYL) 4 METHOXY N (P TOLYL) BENZENESULFONAMIDE; N (4 (DIETHYLAMINO)BENZYL) N (P TOLYL)BENZENESULFONAMIDE; N (4 CHLOROPHENYL) N (4 (DIETHYLAMINO)BENZYL) 4 METHOXYBENZENESULFONAMIDE; RIMONABANT; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; HUMAN; HUMAN CELL; OSTEOCLASTOGENESIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY;

ANIMALS; BIOLOGICAL ASSAY; CANNABINOID RECEPTOR AGONISTS; CHO CELLS; CRICETINAE; LIGANDS; MACROPHAGES; MICE; OSTEOCLASTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, CANNABINOID, CB2; SULFONAMIDES;

EID: 84875150009     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3017464     Document Type: Article

References (44)

1. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992, 258, 1946-1949 (Pubitemid 23026736)
2. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 1995, 50, 83-90
3. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 1995, 215, 89-97
4. Bayewitch, M.; Rhee, M. H.; Avidor-Reiss, T.; Breuer, A.; Mechoulam, R.; Vogel, Z. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase J. Biol. Chem. 1996, 271, 9902-9905 (Pubitemid 26131542)
5. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors Mol. Pharmacol. 1995, 48, 443-450
6. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
7. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65 (Pubitemid 23305569)
8. Hohmann, A. G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives Chem. Phys. Lipids 2002, 121, 173-190 (Pubitemid 36050105)
9. Karsak, M.; Gaffal, E.; Date, R.; Wang-Eckhardt, L.; Rehnelt, J.; Petrosino, S.; Starowicz, K.; Steuder, R.; Schlicker, E.; Cravatt, B.; Mechoulam, R.; Buettner, R.; Werner, S.; Di Marzo, V.; Tuting, T.; Zimmer, A. Attenuation of allergic contact dermatitis through the endocannabinoid system Science 2007, 316, 1494-1497 (Pubitemid 46906619)
10. Palazuelos, J.; Davoust, N.; Julien, B.; Hatterer, E.; Aguado, T.; Mechoulam, R.; Benito, C.; Romero, J.; Silva, A.; Guzman, M.; Nataf, S.; Galve-Roperh, I. The CB2 cannabinoid receptor controls myeloid progenitor trafficking J. Biol. Chem. 2008, 283, 13320-13329
11. Guindon, J.; Hohmann, A. G. The endocannabinoid system and cancer: therapeutic implication Br. J. Pharmacol. 2011, 163, 1447-1463
12. Oesch, S.; Gertsch, J. Cannabinoid receptor ligands as potential anticancer agents - high hopes for new therapies? J. Pharm. Pharmacol. 2009, 61, 839-853
13. Idris, A. I.; Ralston, S. H. Cannabinoids and Bone: Friend or Foe? Calcified Tissue Int. 2010, 87, 285-297
14. Hillard, C. J. Role of cannabinoids and endocannabinoids in cerebral ischemia Curr. Pharm. Des. 2008, 14, 2347-2361
15. Hegde, V. L.; Hegde, S.; Cravatt, B. F.; Hofseth, L. J.; Nagarkatti, M.; Nagarkatti, P. S. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells Mol. Pharmacol. 2008, 74, 20-33 (Pubitemid 351872155)
16. Munoz-Luque, J.; Ros, J.; Fernandez-Varo, G.; Tugues, S.; Morales-Ruiz, M.; Alvarez, C. E.; Friedman, S. L.; Arroyo, V.; Jimenez, W. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats J. Pharmacol. Exp. Ther. 2008, 324, 475-483 (Pubitemid 351185849)
17. Izzo, A. A.; Camilleri, M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects Gut 2008, 57, 1140-1155
18. Pacher, P.; Batkai, S.; Kunos, G. The endocannabinoid system as an emerging target of pharmacotherapy Pharmacol. Rev. 2006, 58, 389-462 (Pubitemid 44394908)
19. Compton, D. R.; Rice, K. C.; De Costa, B. R.; Razdan, R. K.; Melvin, L. S.; Johnson, M. R.; Martin, B. R. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities J. Pharmacol. Exp. Ther. 1993, 265, 218-226 (Pubitemid 23320964)
20. Huffman, J. W. Cannabimimetic indoles, pyrroles and indenes Curr. Med. Chem. 1999, 6, 705-720 (Pubitemid 29399500)
21. Palmer, S. L.; Thakur, G. A.; Makriyannis, A. Cannabinergic ligands Chem. Phys. Lipids. 2002, 121, 3-19 (Pubitemid 36044538)
22. Raitio, K. H.; Salo, O. M.; Nevalainen, T.; Poso, A.; Jarvinen, T. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands Curr. Med. Chem. 2005, 12, 1217-1237 (Pubitemid 40645483)
23. Marriott, K. S.; Huffman, J. W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor Curr. Top. Med. Chem. 2008, 8, 187-204 (Pubitemid 351795769)
24. Yang, P.; Wang, L.; Xie, X. Q. Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential Future Med. Chem. 2012, 4, 187-204
25. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J. M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Breliere, J. C.; Le Fur, G. L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 1998, 284, 644-650 (Pubitemid 28086654)
26. Ross, R. A.; Brockie, H. C.; Stevenson, L. A.; Murphy, V. L.; Templeton, F.; Makriyannis, A.; Pertwee, R. G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630 Br. J. Pharmacol. 1999, 126, 665-672 (Pubitemid 29087845)
27. Huffman, J. W.; Zengin, G.; Wu, M. J.; Lu, J.; Hynd, G.; Bushell, K.; Thompson, A. L.; Bushell, S.; Tartal, C.; Hurst, D. P.; Reggio, P. H.; Selley, D. E.; Cassidy, M. P.; Wiley, J. L.; Martin, B. R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists Bioorg. Med. Chem. 2005, 13, 89-112 (Pubitemid 39575695)
28. Kimball, E. S.; Schneider, C. R.; Wallace, N. H.; Hornby, P. J. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291, G364-371
29. Xi, Z.-X.; Peng, X.-Q.; Li, X.; Song, R.; Zhang, H.-Y.; Liu, Q.-R.; Yang, H.-J.; Bi, G.-H.; Li, J.; Gardner, E. L. Brain cannabinoid CB2 receptors modulate cocaine's actions in mice Nat. Neurosci. 2011, 14, 1160-1166
30. Lunn, C. A.; Fine, J. S.; Rojas-Triana, A.; Jackson, J. V.; Fan, X.; Kung, T. T.; Gonsiorek, W.; Schwarz, M. A.; Lavey, B.; Kozlowski, J. A.; Narula, S. K.; Lundell, D. J.; Hipkin, R. W.; Bober, L. A. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo J. Pharmacol. Exp. Ther. 2006, 316, 780-788 (Pubitemid 43131006)
31. Iwamura, H.; Suzuki, H.; Ueda, Y.; Kaya, T.; Inaba, T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor J. Pharmacol. Exp. Ther. 2001, 296, 420-425 (Pubitemid 32112468)
32. Francisco, M. E.; Seltzman, H. H.; Gilliam, A. F.; Mitchell, R. A.; Rider, S. L.; Pertwee, R. G.; Stevenson, L. A.; Thomas, B. F. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N -(piperidinyl)- 5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1 H -pyrazole-3-carboxamide (SR141716) J. Med. Chem. 2002, 45, 2708-2719 (Pubitemid 34627643)
33. Yang, P.; Myint, K. Z.; Tong, Q.; Feng, R.; Cao, H.; Almehizia, A. A.; Hamed, A. M.; Wang, L.; Bartlow, P.; Gao, Y.; Gertsch, J.; Teramachi, J.; Kurihara, N.; Roodman, G. D.; Cheng, T.; Xie, X. Q. Lead Discovery, Chemistry Optimization and Biological Evaluation Studies of Novel Bi-amide Derivatives as CB2 Receptor Inverse Agonists and Osteoclast Inhibitors J. Med. Chem. 2012, 55, 9973-9987
34. Zhang, Y.; Xie, Z.; Wang, L.; Schreiter, B.; Lazo, J. S.; Gertsch, J.; Xie, X. Q. Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recognition and signal transduction for CB2 receptor Int. Immunopharmacol. 2011, 11, 1303-1310
35. Bab, I.; Zimmer, A.; Melamed, E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss Ann. Med. 2009, 41, 560-567
36. Anandarajah, A. P.; Schwarz, E. M.; Totterman, S.; Monu, J.; Feng, C. Y.; Shao, T.; Haas-Smith, S. A.; Ritchlin, C. T. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis Ann. Rheum. Dis. 2008, 67, 296-301 (Pubitemid 351281261)
37. Myint, K. Z.; Xie, X. Q. Recent advances in fragment-based QSAR and multi-dimensional QSAR methods Int. J. Mol. Sci. 2010, 11, 3846-3866
38. Chen, J. Z.; Han, X. W.; Liu, Q.; Makriyannis, A.; Wang, J.; Xie, X. Q. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach J. Med. Chem. 2006, 49, 625-636 (Pubitemid 43158442)
39. Xie, X. Q.; Melvin, L. S.; Makriyannis, A. The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940 J. Biol. Chem. 1996, 271, 10640-10647 (Pubitemid 26145798)
40. Xie, X. Q.; Chen, J. Z.; Billings, E. M. 3D structural model of the G-protein-coupled cannabinoid CB2 receptor Proteins 2003, 53, 307-319 (Pubitemid 37193825)
41. Gertsch, J.; Leonti, M.; Raduner, S.; Racz, I.; Chen, J. Z.; Xie, X. Q.; Altmann, K. H.; Karsak, M.; Zimmer, A. Beta-caryophyllene is a dietary cannabinoid Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 9099-9104
42. Feng, R.; Anderson, G.; Xiao, G.; Elliott, G.; Leoni, L.; Mapara, M. Y.; Roodman, G. D.; Lentzsch, S. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth Blood 2007, 109, 2130-2138 (Pubitemid 46348215)
43. Xu, J.; Li, Z.; Luo, J.; Yang, F.; Liu, T.; Liu, M.; Qiu, W. W.; Tang, J. Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption J. Med. Chem. 2012, 55, 3122-3134
44. Feng, R.; Ma, H.; Hassig, C. A.; Payne, J. E.; Smith, N. D.; Mapara, M. Y.; Hager, J. H.; Lentzsch, S. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling Mol. Cancer. Ther. 2008, 7, 1494-1505